Unicycive Therapeutics Inc (UNCY)

$6.92 -0.51 (-6.86%)
Market Cap 193.04M
Revenue (ttm) 0.00
Net Income (ttm) -26.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,198,700
Avg Vol 617,388
Day's Range N/A - N/A
Shares Out 26.70M
Stochastic %K 36%
Beta 1.73
Analysts Strong Sell
Price Target $37.89

Company Profile

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I cl...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 351 4495
Address:
1975 West El Camino Real, Suite 204, Mountain View, United States
supplySHOCK
supplySHOCK Jun. 5 at 11:59 PM
$UNCY $RGTZ $CSCO $FPS vvs
0 · Reply
Eagley3k
Eagley3k Jun. 5 at 10:12 PM
$UNCY $50M worth of shares (hopefully at a much higher price) + warrants exercise cash + existing Asia licensing deal which will kick in immediate cash upon approval, should be enough to start hiring those sales reps. Or else a buy-out is announced shortly after. (Imo).
1 · Reply
osubuck30
osubuck30 Jun. 5 at 8:45 PM
$UNCY yep I’m assuming share count around 50 million eventually. Drug potential revenue worldwide with 50% market share will be well north of $1 billion. I think a larger company would pay 1.5-3X that. You can do the math…. $30-$60 value based just on the one drug assuming $1 billion potential.
0 · Reply
osubuck30
osubuck30 Jun. 5 at 8:36 PM
$UNCY yes they are likely preparing for approval….. the whole point of the stock market is to fund companies. The extra $50 million will be diluted at much higher levels. 2 million more shares around $20?
1 · Reply
TwongStocks
TwongStocks Jun. 5 at 8:23 PM
$UNCY ATM agreement amended. Increased from $100M to $150M https://www.sec.gov/ix?doc=/Archives/edgar/data/1766140/000121390026065828/ea0291976-8k_unicycive.htm
2 · Reply
onequick4door
onequick4door Jun. 5 at 5:26 PM
$UNCY made my last big lot purchase $40K at $6.95. TY for that opportunity
1 · Reply
Neurogirl
Neurogirl Jun. 5 at 2:58 PM
$UNCY pretty quiet in here. Took the opportunity to buy more
1 · Reply
osubuck30
osubuck30 Jun. 5 at 2:17 PM
$UNCY ha! This is an undiscovered bio…. On approval the market cap will go straight to $1-$1.5 billion. The drug at that point is worth $1.5 billion to someone else. You can trade around a position but I’m not letting go of any core shares for less than $20.
2 · Reply
Blockybuster
Blockybuster Jun. 5 at 2:00 PM
hold $UNCY and strong buy BFRI its dirt cheap at 12 million valaution while nearing FDA Decision in September could easily double or triple even before potential FDA approval.
1 · Reply
RunFYLife
RunFYLife Jun. 5 at 8:32 AM
$UNCY
0 · Reply
Latest News on UNCY
Unicycive Therapeutics files $150M mixed securities shelf

2026-06-05T20:20:10.000Z - 5 hours ago

Unicycive Therapeutics files $150M mixed securities shelf

Unicycive Therapeutics Registration statement: Registration filing

Jun 5, 2026, 8:00 AM EDT - 13 hours ago

Unicycive Therapeutics Registration statement: Registration filing

Unicycive Therapeutics price target raised to $18 from $15 at Benchmark

2026-06-02T13:07:41.000Z - 3 days ago

Unicycive Therapeutics price target raised to $18 from $15 at Benchmark

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:27 AM EDT - 4 days ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:27 AM EDT - 4 days ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:26 AM EDT - 4 days ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:26 AM EDT - 4 days ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:26 AM EDT - 4 days ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:25 AM EDT - 4 days ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:25 AM EDT - 4 days ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:25 AM EDT - 4 days ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:24 AM EDT - 4 days ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:24 AM EDT - 4 days ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics management to meet virtually with Piper Sandler

2026-05-28T15:05:39.000Z - 8 days ago

Unicycive Therapeutics management to meet virtually with Piper Sandler

Unicycive Therapeutics price target lowered to $37 from $40 at Guggenheim

2026-05-13T11:14:54.000Z - 23 days ago

Unicycive Therapeutics price target lowered to $37 from $40 at Guggenheim

Unicycive Therapeutics Slides: Corporate presentation

May 13, 2026, 7:00 AM EDT - 23 days ago

Unicycive Therapeutics Slides: Corporate presentation

Unicycive Therapeutics reports Q1 EPS (50c), consensus (47c)

2026-05-12T11:51:45.000Z - 24 days ago

Unicycive Therapeutics reports Q1 EPS (50c), consensus (47c)

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026, 7:05 AM EDT - 24 days ago

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Unicycive Therapeutics initiated with a Buy at B. Riley

2026-05-01T14:07:09.000Z - 5 weeks ago

Unicycive Therapeutics initiated with a Buy at B. Riley

Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Apr 9, 2026, 7:05 AM EDT - 2 months ago

Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Unicycive Therapeutics price target lowered to $15 from $21 at Benchmark

2026-04-06T11:30:08.000Z - 2 months ago

Unicycive Therapeutics price target lowered to $15 from $21 at Benchmark

Unicycive Therapeutics price target lowered to $40 from $46 at Guggenheim

2026-04-02T10:59:29.000Z - 2 months ago

Unicycive Therapeutics price target lowered to $40 from $46 at Guggenheim

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Mar 30, 2026, 7:05 AM EDT - 2 months ago

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Unicycive Therapeutics management to meet with Piper Sandler

2026-02-20T14:22:23.000Z - 3 months ago

Unicycive Therapeutics management to meet with Piper Sandler

Unicycive Therapeutics initiated with a Buy at WestPark Capital

2026-02-19T12:57:38.000Z - 3 months ago

Unicycive Therapeutics initiated with a Buy at WestPark Capital

Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Feb 17, 2026, 9:15 AM EST - 3 months ago

Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech Summit

Feb 4, 2026, 7:05 AM EST - 4 months ago

Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech Summit

UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

Jan 29, 2026, 9:15 AM EST - 4 months ago

UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

Unicycive Therapeutics announces FDA acceptance of OLC NDA resubmission

2026-01-29T12:15:28.000Z - 4 months ago

Unicycive Therapeutics announces FDA acceptance of OLC NDA resubmission

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

Jan 29, 2026, 7:05 AM EST - 4 months ago

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

Unicycive Therapeutics resubmits NDA for oxylanthanum carbonate

2025-12-29T12:10:32.000Z - 5 months ago

Unicycive Therapeutics resubmits NDA for oxylanthanum carbonate

Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)

Dec 29, 2025, 7:05 AM EST - 5 months ago

Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)

Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Dec 1, 2025, 1:41 PM EST - 6 months ago

Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Unicycive Therapeutics to Participate in Upcoming Investor Events in December

Nov 25, 2025, 7:05 AM EST - 6 months ago

Unicycive Therapeutics to Participate in Upcoming Investor Events in December

Unicycive Therapeutics reports Q3 EPS (46c), consensus (53c)

2025-11-12T12:21:25.000Z - 7 months ago

Unicycive Therapeutics reports Q3 EPS (46c), consensus (53c)

Unicycive Therapeutics sees cash runway into 2027

2025-11-12T12:21:01.000Z - 7 months ago

Unicycive Therapeutics sees cash runway into 2027

Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 7:05 AM EST - 7 months ago

Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 3, 2025, 7:05 AM EST - 7 months ago

Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Unicycive Therapeutics to present new OLC data at ASN Kidney Week 2025

2025-10-30T11:20:33.000Z - 7 months ago

Unicycive Therapeutics to present new OLC data at ASN Kidney Week 2025

Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference

Oct 30, 2025, 7:05 AM EDT - 7 months ago

Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference

Unicycive Therapeutics price target raised to $22 from $9 at H.C. Wainwright

2025-10-29T10:25:58.000Z - 7 months ago

Unicycive Therapeutics price target raised to $22 from $9 at H.C. Wainwright

Unicycive provides update on meeting with FDA, resubmission of NDA for OLC

2025-10-28T11:10:27.000Z - 7 months ago

Unicycive provides update on meeting with FDA, resubmission of NDA for OLC

Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End

Oct 28, 2025, 7:05 AM EDT - 7 months ago

Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End

UNCY Lawsuit Alert! Class Action Lawsuit Against Unicycive Therapeutics

2025-09-30T13:18:55.000Z - 8 months ago

UNCY Lawsuit Alert! Class Action Lawsuit Against Unicycive Therapeutics

Unicycive Therapeutics to Participate in Upcoming Investor Events in September

Aug 26, 2025, 7:00 AM EDT - 10 months ago

Unicycive Therapeutics to Participate in Upcoming Investor Events in September

Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease

Aug 18, 2025, 7:05 AM EDT - 10 months ago

Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease

Unicycive Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Aug 14, 2025, 3:55 PM EDT - 10 months ago

Unicycive Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 14, 2025, 7:00 AM EDT - 10 months ago

Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology

Jul 24, 2025, 8:00 AM EDT - 11 months ago

Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology

Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 8, 2025, 8:30 AM EDT - 11 months ago

Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

Jul 7, 2025, 7:00 AM EDT - 11 months ago

Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Jun 30, 2025, 7:05 AM EDT - 1 year ago

Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Unicycive Therapeutics, Inc. Announces Reverse Stock Split

Jun 17, 2025, 7:00 AM EDT - 1 year ago

Unicycive Therapeutics, Inc. Announces Reverse Stock Split

supplySHOCK
supplySHOCK Jun. 5 at 11:59 PM
$UNCY $RGTZ $CSCO $FPS vvs
0 · Reply
Eagley3k
Eagley3k Jun. 5 at 10:12 PM
$UNCY $50M worth of shares (hopefully at a much higher price) + warrants exercise cash + existing Asia licensing deal which will kick in immediate cash upon approval, should be enough to start hiring those sales reps. Or else a buy-out is announced shortly after. (Imo).
1 · Reply
osubuck30
osubuck30 Jun. 5 at 8:45 PM
$UNCY yep I’m assuming share count around 50 million eventually. Drug potential revenue worldwide with 50% market share will be well north of $1 billion. I think a larger company would pay 1.5-3X that. You can do the math…. $30-$60 value based just on the one drug assuming $1 billion potential.
0 · Reply
osubuck30
osubuck30 Jun. 5 at 8:36 PM
$UNCY yes they are likely preparing for approval….. the whole point of the stock market is to fund companies. The extra $50 million will be diluted at much higher levels. 2 million more shares around $20?
1 · Reply
TwongStocks
TwongStocks Jun. 5 at 8:23 PM
$UNCY ATM agreement amended. Increased from $100M to $150M https://www.sec.gov/ix?doc=/Archives/edgar/data/1766140/000121390026065828/ea0291976-8k_unicycive.htm
2 · Reply
onequick4door
onequick4door Jun. 5 at 5:26 PM
$UNCY made my last big lot purchase $40K at $6.95. TY for that opportunity
1 · Reply
Neurogirl
Neurogirl Jun. 5 at 2:58 PM
$UNCY pretty quiet in here. Took the opportunity to buy more
1 · Reply
osubuck30
osubuck30 Jun. 5 at 2:17 PM
$UNCY ha! This is an undiscovered bio…. On approval the market cap will go straight to $1-$1.5 billion. The drug at that point is worth $1.5 billion to someone else. You can trade around a position but I’m not letting go of any core shares for less than $20.
2 · Reply
Blockybuster
Blockybuster Jun. 5 at 2:00 PM
hold $UNCY and strong buy BFRI its dirt cheap at 12 million valaution while nearing FDA Decision in September could easily double or triple even before potential FDA approval.
1 · Reply
RunFYLife
RunFYLife Jun. 5 at 8:32 AM
$UNCY
0 · Reply
JDubbs530
JDubbs530 Jun. 5 at 1:08 AM
$UNCY is there a prospective date or still vague junish?
1 · Reply
Eagley3k
Eagley3k Jun. 5 at 12:43 AM
$UNCY @KirkHanna i believe you asked for this 😉. Hope you dont mind him calling it "Unicikov" 🤪 nonetheless, there is so much information here i didnt previouly know. Enjoy if you havnt listened already. A must listen yall. https://open.spotify.com/episode/5WhIql4JAXU6Ml1IYGyW1y?si=nZoa8ArmTXSPRSTL5cQ4ZA
1 · Reply
Eagley3k
Eagley3k Jun. 5 at 12:02 AM
$UNCY 30k sitting on the bid! Noice
1 · Reply
Lupis94
Lupis94 Jun. 4 at 10:38 PM
$UNCY enjoy the trip 🚀
0 · Reply
WALLC
WALLC Jun. 4 at 9:46 PM
$UNCY more
0 · Reply
CalebCutts
CalebCutts Jun. 4 at 7:02 PM
$UNCY I'm buying a call, wish me luck 🤞
1 · Reply
Eagley3k
Eagley3k Jun. 4 at 3:59 PM
$UNCY
0 · Reply
VCV86
VCV86 Jun. 4 at 3:36 PM
$UNCY
0 · Reply
Merlintrader
Merlintrader Jun. 4 at 12:54 PM
$LNTH $SPRO $UNCY June 2026 PDUFA Watchlist: Small and Mid-Cap Biotech Catalysts Beyond Big Pharma https://www.merlintrader.com/june-pdufa-watchlist/
0 · Reply
Eagley3k
Eagley3k Jun. 4 at 2:43 AM
$UNCY https://ir.unicycive.com/events-presentations/ir-calendar/detail/17825/virtual-fireside-chat-with-piper-sandler If you havnt listened to this Pipersandler fireside chat i suggest you do. Management answered and cleared all confusion about all the points that many have discussed here.
2 · Reply
chanakyaphrma
chanakyaphrma Jun. 4 at 12:38 AM
$UNCY fda positive decision
0 · Reply
Eagley3k
Eagley3k Jun. 4 at 12:30 AM
$UNCY wonder if they will announce a licensing deal ex US with some upfront payment and sales royalties. Its a $2.5B market globally.
0 · Reply